Paper Details

  1. Home
  2. Paper Details

Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.

Author: DhillonSohita

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Rivastigmine is a cholinesterase inhibitor used to treat Alzheimer's disease. The transdermal patch formulation was found to be effective in improving cognitive and global function, and was generally better tolerated than the oral formulation.
Paper Details　
Original Abstract of the Article :
Rivastigmine, a cholinesterase inhibitor, is available as a transdermal patch (Exelon(®) patch, Rivastach(®) patch, Prometax(®) patch) for the treatment of mild to moderate Alzheimer's disease. Rivastigmine transdermal patch was effective, in terms of improving cognitive and global function, and gen...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2165/11206380-000000000-00000

データ提供：米国国立医学図書館（NLM）

Rivastigmine Transdermal Patch: A New Frontier in Alzheimer's Disease Treatment

Alzheimer's disease, a devastating neurological condition, affects millions worldwide. This study investigates the effectiveness and tolerability of rivastigmine transdermal patch, a novel treatment option for patients with mild to moderate Alzheimer's disease. The researchers conducted a comprehensive evaluation of the patch's impact on cognitive function, global function, and overall tolerability.

The study revealed that rivastigmine transdermal patch was effective in improving cognitive and global function in patients with Alzheimer's disease. Furthermore, the patch was generally well tolerated, with fewer gastrointestinal side effects than oral rivastigmine. The researchers found that the patch had good skin adhesion and tolerability, making it a potentially more convenient and comfortable treatment option for patients.

A More Convenient and Comfortable Treatment Option for Alzheimer's Disease

This study offers promising evidence for the efficacy and tolerability of rivastigmine transdermal patch as a treatment option for Alzheimer's disease. The patch's convenience and improved tolerability profile may enhance patient adherence and improve overall treatment outcomes. The findings suggest that rivastigmine transdermal patch could play a significant role in improving the quality of life for patients with Alzheimer's disease.

Dr. Camel's Conclusion

This study offers a glimmer of hope in the vast desert of Alzheimer's disease research. The development of rivastigmine transdermal patch represents a significant advancement in treatment options, offering a more convenient and potentially more effective approach for patients. As researchers, we must continue to explore innovative therapies and technologies to combat this devastating disease.

Date :
  1. Date Completed 2011-10-11
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

21711064

DOI: Digital Object Identifier

10.2165/11206380-000000000-00000

Related Literature

Article Analysis
・Effects of rivastigmine transdermal patch
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.